According to GuruFocus Insider Data, these are the largest CEO buys during the past week.
New Fortress Energy LLC CEO bought 186,099 shares
New Fortress Energy LLC (NFE, Financial) CEO and 10% Owner Wesley R. Edens bought 186,099 shares on March 29 at a price of $11.29. The price of the stock has increased by 12.05% since.
The energy infrastructure company delivers energy solutions to customers so they can use natural gas for power. The company has a market cap of $2.12 billion. Its shares were trading at $12.65 on April 5.
On Jan. 30, the company announced the pricing of its initial public offering of 20 million Class A shares at $14 per share.
Edens also bought 592,100 shares on March 28 at a price of $9.84.
Director David J. Grain bought 4,500 shares on April 1 at a price of $11.29. The price of the stock has increased by 12.05% since.
Director Matthew Wilkinson bought 12,500 shares on March 28 at a price of $9.97. The price of the stock has increased by 26.88% since.
Director and 10% Owner Randal A. Nardone bought 580,000 shares on March 28 at a price of $9.85. The price of the stock has increased by 28.43% since.
EQT Corp. CEO bought 12,660 shares
EQT Corp. (EQT, Financial) President and CEO Robert Joseph Mcnally bought 12,660 shares on March 29 at a price of $20.80. The price of the stock has increased by 3.89% since.
EQT is a natural gas exploration and production company. It produces natural gas from proved natural gas, natural gas liquid and crude oil reserves; and also provides gathering, transmission and storage services for the company's produced gas. The company has a market cap of $5.51 billion. Its shares traded at $21.61 as of April 5.
Net loss for the fourth quarter of 2018 was $598 million compared to $1.28 billion for the prior-year quarter.
Senior Vice President and Chief Financial Officer Jimmi Sue Smith bought 6,000 shares on March 14 at a price of $19.79. The price of the stock has increased by 9.2% since.
Director Daniel J. Rice IV bought 1,025 shares on April 1 at a price of $20.74. The price of the stock has increased by 4.19% since.
Director Gerald F. MacCleary bought 1,085 shares on April 1 at a price of $20.74. The price of the stock has increased by 4.19% since.
Director A. Bray Cary Jr. bought 1,205 shares on April 1 at a price of $20.74. The price of the stock has increased by 4.19% since.
Executive Vice President of Production Erin R. Centofanti bought 7,765 shares on March 29 at a price of $20.83. The price of the stock has increased by 3.74% since.
OPKO Health CEO bought 80,000 shares
OPKO Health Inc. (OPK, Financial) CEO, Chairman, and 10% Owner Phillip Frost bought 80,000 shares during the past week at the average price of $2.54.
The diversified health care company seeks to establish industry-leading positions in large, rapidly growing markets. The company has a market cap of $1.61 billion. Its shares traded at $2.61 as of April 5.
Net loss for the first quarter of 2018 was $43.1 million compared to a net loss of $34.5 million for the comparable period of 2017.
Frost bought 40,000 shares on March 18 at a price of $2.47; 100,000 shares on March 27 at a price of $2.49; 20,000 shares on April 1 at a price of $2.58; 40,000 shares on April 2 at a price of $2.53; and 20,000 shares on April 4 at a price of $2.53. The price of the stock has increased by 3.16% since.
Esperion Therapeutics CEO bought 5,000 shares
Esperion Therapeutics Inc. (ESPR, Financial) President and CEO Timothy M. Mayleben bought 5,000 shares on March 29 at a price of $40.00. The price of the stock has increased by 7.4% since.
Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C. The company has a market cap of $1.15 billion. Its shares traded at $42.96 as of April 5.
Net loss for the fourth quarter of 2018 was $60.04 million compared to $37.89 million for the prior-year period.
Mayleben bought 5,000 shares on March 14 at a price of $48.73 and 5,000 shares on March 20 at a price of $43.48.
Chief Financial Officer Richard Bartram sold 8,000 shares on March 3 at a price of $42.88. The price of the stock has increased by 0.19% since.
10% Owner Biotech Target N. V. bought 50,000 shares on March 14 at a price of $49.89. The price of the stock has decreased by 13.89% since.
Director Nicole Vitullo sold 15,329 shares on March 19 at a price of $44.73. The price of the stock has decreased by 3.96% since.
Director Roger S. Newton sold 25,000 shares on March 12 at a price of $50.06. The price of the stock has decreased by 14.18% since.
For the complete list of stocks that bought by their company CEOs, go to: CEO Buys.
Disclosure: I do not own stock in any of the companies mentioned in the article.
